Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer’s Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes

calendar_today September 1, 2026 person alzheon domain alzheon

John A. Hey, Susan Abushakra, Aidan Power, David Watson, Anton Porsteinsson, Marwan Sabbagh, Emer MacSweeney, Sharon Cohen, Mercè Boada, P. Murali Doraiswamy, Fanny M.

open_in_new Read original post

Discovery

Learnings

Guidance

Toolbox

Alignment

API Evangelist LLC

Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer’s Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes